The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Amgen said on Tuesday its chief financial ​officer, Peter Griffith, would retire, with ‌Thomas Dittrich taking over the role in September.

Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020.

At least ​20 people ‌in Japan who ​took ​Amgen's rare disease ⁠drug ​have died, ​while 22 others developed ​potentially ​fatal liver injuries, ‌the ⁠Wall Street Journal reported ​on ​Friday, ⁠citing partner ​Kissei ​Pharmaceutical.

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

On a recent episode of The Compound and Friends, hosts Josh Brown and Michael Batnick sat down with former Janus analyst Matt Ancrum to discuss his study of 100-bagger stocks.

On May 11, 2026, we delve into the discounted cash flow (DCF) analysis for Amgen Inc (AMGN), a company that has shown a price performance of +25.8% over the pas

Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.